Liquidia announces presentation on open-label safety study of L606 at ATS 2024

Liquidia Corporation will present data related to the investigational use of L606 inhalation suspension in people with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease at the American Thoracic Society 2024 International Conference, taking place May 17-22, 2024, in San Diego, California. Rajeev Saggar, MD, chief medical officer at Liquidia, said: “We are pleased to be presenting initial data on the safety and tolerability of L606 from our on-going, open-label study in the United States. We believe that the initial data supports our continued confidence that twice-daily dosing is tolerable, titratable and supports further investigation as we prepare to initiate a global, pivotal efficacy trial later this year.” The Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD in the short-term and long-term. The trial is enrolling patients in two groups categorized as ‘transition’ and ‘naive.’ The transition group includes participants with PAH or PH-ILD who transitioned from nebulized Tyvaso or Tyvaso DPI to L606. The naive group is comprised of participants with PAH who added L606 to no more than two non-prostacyclin oral therapies.